Natural History of Growth Hormone Deficiency in a Pediatric Cohort

Eva Deillon, Michael Hauschild, Mohamed Faouzi, Sophie Stoppa-Vaucher, Eglantine Elowe-Gruau, Andrew Dwyer, Gerald E. Theintz, Jean-Michel Dubuis, Primus E. Mullis, Nelly Pitteloud, and Franziska Phan-Hug

Division of Endocrinology, Diabetology and Obesity, Department of Pediatrics, and Center of Clinical Epidemiology, University Hospital Lausanne, and Department of Endocrinology, Diabetology and Metabolism (EDMD), Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne, Groupe Médical du Grand-Lancy, Geneva, and Division of Pediatric Endocrinology, Diabetology and Metabolism and Department of Clinical Research, University Children's Hospital, Inselspital, Bern, Switzerland

Key Words
Growth hormone deficiency · Growth hormone · IGF-1 · Transition · Predictors

Abstract
Background/Aims: Controversies still exist regarding the evaluation of growth hormone deficiency (GHD) in childhood at the end of growth. The aim of this study was to describe the natural history of GHD in a pediatric cohort. Methods: This is a retrospective study of a cohort of pediatric patients with GHD. Cases of acquired GHD were excluded. Univariate logistic regression was used to identify predictors of GHD persisting into adulthood. Results: Among 63 identified patients, 47 (75%) had partial GHD at diagnosis, while 16 (25%) had complete GHD, including 5 with multiple pituitary hormone deficiencies. At final height, 50 patients underwent repeat stimulation testing; 28 (56%) recovered and 22 (44%) remained growth hormone (GH) deficient. Predictors of persisting GHD were: complete GHD at diagnosis (OR 10.1, 95% CI 2.4–42.1), pituitary stalk defect or ectopic pituitary gland on magnetic resonance imaging (OR 6.5, 95% CI 1.1–37.1), greater height gain during GH treatment (OR 1.8, 95% CI 1.0–3.3), and IGF-1 level <-2 standard deviation scores (SDS) following treatment cessation (OR 19.3, 95% CI 3.6–103.1). In the multivariate analysis, only IGF-1 level <-2 SDS (OR 13.3, 95% CI 2.3–77.3) and complete GHD (OR 6.3, 95% CI 1.2–32.8) were associated with the outcome. Conclusion: At final height, 56% of adolescents with GHD had recovered. Complete GHD at diagnosis, low IGF-1 levels following retesting, and pituitary malformation were strong predictors of persistence of GHD.

Introduction

Among children presenting with short stature, approximately 10% have pathologic growth hormone deficiency (GHD) [1]. The diagnosis of GHD is based on clinical presentation and results of dynamic testing [2, 3]. Growth hormone (GH) replacement therapy is an effective treatment in these children. Continuing GH treatment at the end of growth remains a clinically important question since GH is also available for adults [4]. Beneficial effects of GH treatment in adults include: increased periosteal bone formation and muscle mass, decreased fat mass, improved lipid profile and psychological well-being [5–10]. However, possible negative effects of GH treatment include: increased insulin resistance, fluid retention with occasional edema,
pseudotumor cerebri, and carpal tunnel syndrome [9, 11]. Furthermore, there are growing concerns about the long-term effects of GH treatment with recent reports of an increased risk of cardiovascular events, especially hemorrhagic stroke in adults treated with GH during childhood [12–14]. For childhood-onset GHD, the transition period from adolescence to adulthood represents a critical time for reassessing GH status. At completion of growth (defined by bone age >14 years in girls and >16 years in boys or growth velocity <2 cm/year), about 40% of patients remain GH deficient in adulthood [15]. Importantly, as summarized in table 1, there is yet no consensus regarding the evaluation of GHD in adolescents at the end of growth in order to define which patients will benefit from continued GH treatment despite a variety of protocols and proposed thresholds to address this question [2, 11, 15–19].

Therefore, this study aimed to describe the natural history of GHD in a cohort of adolescents during the transition period and to identify predictors of GHD continuing into adulthood.

### Research Design and Methods

We studied a cohort of children with GHD who were treated at the University Hospital of Lausanne from 1998 to 2011. Adolescents who completed growth with bone age >14 years in girls and >16 years in boys or growth velocity <2 cm/year were included. Cases of acquired GHD (i.e., trauma or oncology treatments) and individuals receiving GH for other indications (i.e., Turner syndrome, small for gestational age, SHOX gene haploinsufficiency, and chronic renal insufficiency) were excluded.

The diagnosis of GHD was based on the results of two provocation tests [insulin tolerance test (ITT), arginine (ARG) test, or glucagon test with peak GH <10 μg/l] or one pathological test associated with structural pituitary abnormalities such as hypoplasia, stalk defect, or ectopic posterior pituitary on magnetic resonance imaging (MRI) [3]. Priming with sex steroids was used before the stimulation test in prepubertal children >10 years of age. GH treatment was conducted in a dose-dependent manner (0.15–0.20 mg/kg/week) to normalize IGF-1 levels [between –2 and 2 standard deviation scores (SDS)].

At completion of growth, GH status was reassessed by dynamit testing and by serum IGF-1 measurement following a GH treatment cessation (1–4 months). The ARG test was proposed in the majority of cases because of better tolerance compared to other tests [16]. Adolescents with multiple (>2) pituitary hormone [GH, adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle stimulating hormone (FSH), or thyroid-stimulating hormone (TSH)] deficiencies [20, 21] were considered GH deficient without retesting and GH treatment was continued into adulthood without interruption.

We defined complete GHD as a peak GH <5 μg/l and partial GHD as a peak GH ≥5–10 μg/l following stimulation at diagnosis and at final height, as proposed in prior studies [15, 17]. The decision to continue GH treatment was based on the 1998 Growth Hormone Research Society recommendations (peak GH of <3 μg/l) [11]. The study was approved by the local ethics committee.

GH concentrations were determined using a chemiluminescent immunoassay (CIA) with a System Luminometer 400 (Nich-
ols Institute Diagnostics, Bad Nauheim, Germany; study period 1998–2004). The CIA assay has an analytical sensitivity of 0.2 μg/l with an intra-assay coefficient of variation (CV) of 4.0–5.4% and an inter-assay CV of 7.9–9.2%. From 2004 on, the automated CIA Immulite 2000 (Siemens Healthcare Diagnostics Inc., Erlangen, Germany) was used with an analytical sensitivity of 0.05 μg/l, an intra-assay CV of 2.9–4.6%, and an inter-assay CV of 4.2–6.6%. The GH calibration standard used for both platforms was the WHO NIBSC (1st 80/505 until December 2009 and 2nd 98/574 thereafter). IGF-1 concentrations were determined by a radioimmunoassay from Nichols Institute Diagnostics (study period 1998–2005). The radioimmunoassay had an analytical sensitivity of 15 μg/l, an intra-assay CV of 2.4–3.0%, and an inter-assay CV of 5.2–8.4%. From 2005 on, the automated CIA Immulite 2000 (Siemens Healthcare Diagnostics Inc.) was used. The automated assay has an analytical sensitivity of 35 μg/l, an intra-assay CV of 2.3–3.9%, and an inter-assay CV of 3.7–8.1%. The WHO NIBSC 1st IRR 87/518 was used for IGF-1 calibration throughout the entire study period. IGF-1 data were transformed into sex- and age-related SDS values using previously published data [22].

**Statistical Analysis**

Data are presented as means ± standard deviations (SD). Categorical data are presented using descriptive statistics. Predictors of persisting GHD were examined using logistic regression analysis. The strength of the association measured by the odds ratio (OR) and significant predictors at the level of 5% from the univariate analysis were used in a forward procedure to fit a multivariate model. Confirmation of OR results included nonparametric bootstrap analysis (replication ×100). Data analysis was performed using STATA-12 software (Stata Statistical Software, release 12, StataCorp 2011, College Station, Tex., USA).

**Results**

One hundred and sixty-two children with GHD were treated at the University Hospital of Lausanne between 1998 and 2011, 82 of whom had completed their growth. Of these 82 patients, 19 (23%) had acquired forms of GHD and were excluded, while the remaining 63 adolescents with congenital or idiopathic GHD (77%) were included in the analysis.

**Characteristics of the GH-Deficient Cohort at Diagnosis**

Three quarters of the cohort (47/63) exhibited partial GHD (75%), while 16/63 had complete GHD (25%) (fig. 1). In total, 42 (67%) were boys and 21 (33%) girls. The diagnosis was made at a mean age of 9.5 ± 3.6 years. The mean height was –2.4 ± 0.7 SDS at diagnosis with a delayed bone age of 2.2 ± 1.1 years. Twenty subjects (20/63) exhibited pituitary malformation (32%) including 11/20 with complete GHD (55%) and 9/20 with partial GHD (45%) at diagnosis (fig. 1). Six boys and 2 girls (>10 years of age) were diagnosed with partial GHD after priming with sex steroids. Clinical, radiologic, and biochemical characteristics of subgroups (partial GHD, n = 47, and complete GHD, n = 16) are presented in table 2. All patients with partial GHD had isolated GHD, while patients with complete GHD included 5 children with multiple pituitary hormone deficiencies (MPHD). Three children had >2 pituitary hormone deficiencies associated with SOD (n = 1) and ectopic posterior pituitary gland (n = 2). The 2 other children with MPHD included 1 girl with TSH and GH deficiencies associated with stalk defect and ectopic posterior pituitary gland on MRI and 1 boy with GH and LH/FSH deficiency as well as pituitary hypoplasia (table 2).

**GH Reassessment at Final Height**

At final height, 50/63 children were retested for GHD (fig. 1). Three patients with MPHD were considered GH deficient without treatment interruption and were integrated into statistical analyses as GH deficient. The other 10 were lost to follow-up. The vast majority of patients (47/50) underwent ARG testing, while 2 had an ARG-ITT test and 1 an ITT. Nine out of 50 (18%) patients showed complete GHD, 13/50 (26%) partial GHD, and 28/50 (56%) recovered. The rate of reversal (according to different cutoffs) among the diagnostic subgroups is presented in figure 1. Seven of the 63 patients in this cohort continued GH treatment into adulthood: 4 had a peak GH <3 μg/l and an IGF-1 level <-2 SDS and 3 patients with MPHD (>2) were considered GH deficient at adulthood (fig. 1).

**GH Reassessment of Patients with Partial GHD at Diagnosis**

Of the 47 patients with partial GHD at initial diagnosis, 37 had repeat stimulation testing at final height (fig. 1). In total, 25/37 (68%) patients recovered, 9/37 (24%) patients remained with partial GHD, and 3/37 (8%) patients worsened to complete GHD (fig. 1, 2). Importantly, no adolescent initially diagnosed with partial GHD had a GH peak <3 μg/l and none of these patients continued GH treatment into adulthood. The 3 adolescents who had worsening deficiency with complete GHD at final height had a peak GH between 3 and 5 μg/l. Two had an IGF-1 level =>2 SDS and no pituitary abnormalities on MRI, while 1 patient exhibited ectopic posterior pituitary on MRI at final height.

Four of the 9 children that remained partially GH deficient showed IGF-1 levels <-2 SDS. One had pituitary hypoplasia. Of the 25/37 patients who recovered from partial GH deficiency, 3 had pituitary malformations (2...
with hypoplasia and 1 with ectopic posterior pituitary), while IGF-1 levels were ≥–2 SDS. The other 22 patients without pituitary anomalies had idiopathic GHD (88%). Two of these children had IGF-1 levels <–2 SDS but a GH peak >20 μg/l (fig. 1).

GH Reassessment of Patients with Complete GHD at Diagnosis

Thirteen of the 16 patients had a stimulation test at final height (fig. 1). Nearly half of the patients remained with complete GHD after stimulation (6/13, 46%), while 4/13 (31%) patients improved to partial GHD and 3/13 (23%) patients recovered (fig. 1, 2). Three patients with MPHD were considered GH deficient without testing.

One of the children with complete GHD (peak GH level 3.3 μg/l after ARG test) was not treated as the peak GH was >3 μg/l [11]. This child had ectopic posterior pituitary on MRI but exhibited IGF-1 levels >–2 SDS after treatment interruption.

Two adolescents who improved to partial GHD had IGF-1 <–2 SDS. One had idiopathic GHD, while the other had stalk defect and ectopic posterior pituitary. In addition, the latter had MPHD (GH and TSH). One of the 3 children with recovery showed MPHD (GH and FSH/LH) associated with pituitary hypoplasia and severe obesity. Following puberty induction and weight loss, this adolescent recovered from GHD and gonadotropin deficiency. The 2 others had isolated GHD (fig. 1, 2).
GH Reassessment According to Pituitary Anomalies at Diagnosis

At final height, 15/20 young patients with pituitary anomalies at diagnosis were reevaluated by stimulation test, and 3 children with MPHD were considered GH deficient (fig. 1). Among the patients with pituitary malformation, 5 (33%) recovered, including 1 out of 5 retested patients with ectopic posterior pituitary gland. Only 1 patient with ectopic posterior pituitary gland showed a GH peak <5 μg/l (fig. 1). In our series, 35 patients had no pituitary malformation. Of those, 23 (66%) recovered.

IGF-1 Reassessment at Final Height after Treatment Interruption

Plasma IGF-1 levels after treatment interruption were measured in 52/63 adolescents. In 14 adolescents, IGF-1 levels were <–2 SDS at reevaluation (table 2). Two adolescents who showed IGF-1 levels <–2 SDS recovered. These 2 children showed no pituitary malformation and peak GH levels at reassessment of >20 μg/l.

Predictors of Persisting GHD at Final Height

We evaluated several factors predicting the persistence of GHD into adulthood (table 3). Positive predictors included: (1) IGF-1 levels <–2 SDS following discontinuation of GH treatment (OR 19.3); (2) complete GHD at diagnosis in childhood (OR 10.1); (3) pituitary malformation at diagnosis (OR 5.6), especially stalk defect and/or ectopic posterior pituitary (OR 6.5), and (4) height gain of 1 SDS on treatment (OR 1.8). Data are summarized in table 3.

When multivariate logistic regression was used, only complete GHD at diagnosis and an IGF-1 level <–2 SDS following GH treatment cessation were significant as independent positive predictors. Furthermore, when these two factors were combined, the sensitivity and specificity was the highest. The obtained Hosmer-Lemeshow test of goodness-of-fit p value was 0.68 and the area under the ROC curve was 0.81 (fig. 3).

Table 2. Clinical, radiologic, and biochemical characteristics of 63 children with childhood-onset GHD divided into diagnostic subgroups

<table>
<thead>
<tr>
<th></th>
<th>Partial/ isolated GHD (n = 47)</th>
<th>Complete GHD (n = 16)</th>
<th>MPHD (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical and radiological characteristics at diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>9.5±3.6</td>
<td>9.0±4.7</td>
<td>9.5±7.4</td>
</tr>
<tr>
<td>Sex ratio, f/m</td>
<td>17/30</td>
<td>2/9</td>
<td>2/3</td>
</tr>
<tr>
<td>Height SDS</td>
<td>–2.4±0.6</td>
<td>–2.7±0.8</td>
<td>–2.1±1.3</td>
</tr>
<tr>
<td>BMI SDS</td>
<td>–0.2±2.1</td>
<td>0.7±2.0</td>
<td>3.7±3.5</td>
</tr>
<tr>
<td>Delayed bone age, years</td>
<td>2.1±1.06 (n = 38)</td>
<td>2.5±1.6</td>
<td>2.1±1.2</td>
</tr>
<tr>
<td>Pituitary on MRI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoplasia/aplasia</td>
<td>6</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Stalk defect</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Ectopic posterior pituitary</td>
<td>2</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Septo-optic dysplasia</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

**Clinical and biochemical characteristics at final height (cessation of GH treatment)**

<table>
<thead>
<tr>
<th></th>
<th>Partial/ isolated GHD (n = 47)</th>
<th>Complete GHD (n = 16)</th>
<th>MPHD (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>16.6±1.3</td>
<td>16.8±1.9</td>
<td>18.0±2.1</td>
</tr>
<tr>
<td>Final height SDS</td>
<td>–0.89±0.7</td>
<td>–0.7±1.8</td>
<td>0.1±1.5</td>
</tr>
<tr>
<td>Height gain SDS</td>
<td>1.47±0.7</td>
<td>1.99±1.38</td>
<td>2.19±2.13</td>
</tr>
<tr>
<td>IGF-1 &lt;–2 SDS, n/total n</td>
<td>6/38</td>
<td>6/11</td>
<td>2/3</td>
</tr>
</tbody>
</table>

Values are means ± SD or numbers, unless otherwise indicated.
We studied the natural history of GHD (excluding acquired cases) in a cohort of 63 children. Our retrospective study revealed that 44% of adolescents remained deficient at the end of growth, while 56% had recovered. As expected, the majority (89%) of those adolescents who had recovered had partial GHD at diagnosis. Yet, more than half (54%) of the children with complete GHD improved, with nearly a quarter (23%) exhibiting recovery. Furthermore, 8% of the patients with partial GHD at diagnosis worsened and had complete GHD at reevaluation, but none of these children met the criteria for GH treatment into adulthood. These data suggest a plasticity of the GH axis among children diagnosed with GHD.

We identified several predictors of persistent GHD in adulthood: IGF-1 <–2 SDS at reassessment (OR 19), complete versus partial GHD at diagnosis (OR 10), pituitary malformations versus idiopathic GHD (OR 5.6), and height gain of >1 SDS after treatment (OR 1.8). These findings are clinically important as they can help to direct the reassessment of those patients who may require ongoing GHD treatment into adulthood.

This work departs from previous studies in that we excluded acquired GHD and focused exclusively on congenital and idiopathic forms of GHD. The rationale for excluding acquired forms was that the potentially confounding variables introduced by oncological treatment, tumor, or trauma make the interpretation of the natural history data much less clear. Instead, we concentrated on a cohort with potentially, yet likely, genetic etiology underlying GHD.

The retrospective study is limited by the relatively small sample size, as evidenced by quite wide confidence intervals. Therefore, harmonization of stimulation testing and establishing set cutoff values in a prospective multicenter approach seems imperative for future studies to clarify the reassessment of GH status.

### Table 3. Predictors of persisting GHD at the end of growth (final height)

<table>
<thead>
<tr>
<th>Predictors</th>
<th>OR</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-1 &lt;–2 SDS (1–4 months after GH treatment cessation)</td>
<td>19.3</td>
<td>3.6–103.1</td>
<td>0.001</td>
</tr>
<tr>
<td>Complete GHD vs. partial GHD at diagnosis</td>
<td>10.1</td>
<td>2.4–42.1</td>
<td>0.001</td>
</tr>
<tr>
<td>Pituitary malformation on MRI vs. idiopathic GHD</td>
<td>5.6</td>
<td>1.6–19.4</td>
<td>0.006</td>
</tr>
<tr>
<td>Stalk defect/ectopic posterior pituitary vs. idiopathic GHD</td>
<td>6.5</td>
<td>1.1–37.1</td>
<td>0.035</td>
</tr>
<tr>
<td>Height gain (by 1 SDS) during treatment</td>
<td>1.8</td>
<td>1.0–3.3</td>
<td>0.048</td>
</tr>
<tr>
<td>Sex</td>
<td>2.29</td>
<td>0.72–7.3</td>
<td>0.163</td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>0.91</td>
<td>0.79–1.06</td>
<td>0.224</td>
</tr>
<tr>
<td>Bone age retardation (years)</td>
<td>1</td>
<td>0.85–1.17</td>
<td>0.964</td>
</tr>
<tr>
<td>Height at diagnosis (SDS)</td>
<td>0.73</td>
<td>0.34–1.59</td>
<td>0.428</td>
</tr>
<tr>
<td>Weight at diagnosis (SDS)</td>
<td>1.04</td>
<td>0.73–1.48</td>
<td>0.847</td>
</tr>
<tr>
<td>BMI at diagnosis (SDS)</td>
<td>1.05</td>
<td>0.81–1.36</td>
<td>0.723</td>
</tr>
<tr>
<td>Puberty retardation (standardized)</td>
<td>1.04</td>
<td>0.79–1.06</td>
<td>0.84</td>
</tr>
</tbody>
</table>

* Age at puberty onset – mean age at puberty onset according to Tanner for a reference population.

### Fig. 3. Diagnostic performance of complete GHD at diagnosis and IGF-1 levels after treatment cessation for predicting persisting GHD at the end of growth (final height). These two predictors have a discrimination power of 81% (area under the ROC curve = 0.8118). Complete GHD defined by peak GH response <5 μg/l after stimulation. AUC = Area under the ROC curve.
Importantly, we identified predisposing factors for persistence of GHD, such as IGF-1 levels. Indeed, the relationship between IGF-1 levels and GH peak has been previously demonstrated [15]. Yet, IGF-1 levels < –2 SDS have not been shown to be particularly sensitive predictors (46%), but have a specificity of 100% (table 1) [16]. Secco et al. [28] evaluated the accuracy of IGF-1 measures in defining permanent GHD. The ROC curve analysis of IGF-1 showed the best diagnostic accuracy with lower IGF-1 levels, i.e. –2.83 SDS (table 1). In contrast, Quigley et al. [27] studied potential predictors of persisting GHD and found that IGF-1 levels did not have a positive predictive value. They proposed using IGF-1 levels > 1.6 SDS to predict GH sufficiency. The 2 adolescents who recovered with IGF-1 levels < –2 SDS in our cohort point to the problem of using only one factor to identify persisting GHD. However, the sensitivity for predicting persisting GHD was improved when an additional factor (complete GHD at diagnosis) was added (fig. 3).

In the present study, gain of height during treatment was identified as a novel predictor of persisting GHD (OR 2). As our patients were treated in a dose-adjusted manner, this is consistent with a greater GH treatment effect in those patients with more severe GHD and is in line with a better response to GH treatment in patients with pituitary imaging abnormalities. Thus, a more severe phenotype may be indicative of GHD persisting into adulthood [25, 27]. However, there is a need for reassessment of this population to identify patients who may recover function.

The recovery rate of 20% in our patients with ectopic posterior pituitary is similar to rates reported by Gelwane et al. [29] who identified recovery (peak GH > 10 μg/l) in 6 of 24 (25%) patients with ectopic posterior pituitary. In contrast to prior studies [30, 31], we did not find permanent severe GHD in 100% of patients with pituitary stalk interruption syndrome.

Among those patients with partial GHD at diagnosis, none had a GH peak < 3 μg/l at reassessment, yet 6 of the patients had IGF-1 levels < –2 SDS after treatment interruption. Thus, it appears that an IGF-1 level > –2 SDS in a patient with partial GHD would not necessarily require dynamic testing. This would be a novel clinical implication emerging from these data. In effect, such a practice would reduce the number of repeat stimulation tests in young patients diagnosed with partial GHD and should have time- and cost-saving impacts while reducing the risk of adverse testing events.

Despite these novel findings, several important questions relating to GH reassessment at the end of growth remain unanswered. Salient issues include the optimal test and cutoffs, GH immunoassay sensitivity, and clinical outcomes in patients with or without treatment. Also, the time of retesting warrants further examination, as Darendeliler et al. [23] demonstrated that 69% of children with partial GHD recover prior to completion of growth. As summarized in table 1, stimulation tests have a huge variability in cutoff values depending on age and test used. The fact that recommendations have changed over time further complicates retrospective interpretations, which explains why we and others have utilized different cutoffs [15, 17]. Importantly, it remains to be clarified if adopting higher thresholds for stimulated GH peak in young adults could be beneficial for long-term bone health and fracture protection. GH has important effects on bone formation, particularly cortical thickness [32, 33]. Using appropriate size corrections, bone density in children with isolated GHD is normal [34]. Indeed, supplementation of GH increases bone turnover and increases trabecular bone score reflecting bone remodeling in favor of improving its quality [35]. However, there is yet no clear evidence of increased fracture risk of patients with childhood-onset isolated GHD [10]. Achieving final adult height occurs much earlier than the acquisition of peak bone mass and muscle strength [36]. Accordingly, continuation of GH treatment at the end of growth could also help op-
timize muscle development, which may in turn have a positive effect on bone strength and may minimize fracture risk.

During transition, the ITT is the gold standard test. The GH-releasing hormone (GHRH)-ARG test with a similar sensitivity and specificity as shown in table 1 can be used as an alternative, but proposed cutoff values for this test show a high variability that seems to be related to body mass index (BMI) [16, 19]. The proposed threshold GH value after ITT among young adults is 6.1 μg/l [37]. Using this threshold, more patients would have been identified for GH treatment at the end of growth (19/50, vs. 4/50 patients). This includes 10 additional patients with partial GHD and 5 patients with complete idiopathic GHD. To identify the cutoff value proposed by Maghnie et al. [38], or more recently the cutoff value of 5.6 μg/l proposed by Secco et al. [28], MPHD and/or pituitary malformation was used as the gold standard to define probable permanent GHD. However, this is not perfect as we and others have demonstrated that patients with pituitary malformation as well as MPHD can recover [17]. In addition, androgen treatment in those GHD patients with pubertal delay may be another important factor. For instance, recovery of hypothalamic-pituitary-gonadal axis function has been demonstrated in patients with Kallmann syndrome following sex steroid treatment [39, 40]. Furthermore, there is a genetic overlap between gonadotropin-releasing hormone (GnRH) deficiency and MPHD [41], thus suggesting a possible molecular basis for the recovery observed in these two developmental endocrine disorders. So, questions regarding an accepted gold standard remain. Further, standardized GH assays with appropriate quality control are critical for interpreting results [3, 11, 42]. Importantly, this aspect has not been given much attention to this point in time and merits consideration when relevant thresholds to guide clinical management are established.

While predictors can be useful in guiding care during the transition period, none of these factors will have a 100% specificity and sensitivity. Indeed, long-term follow-up of adolescents receiving GH therapy seems appropriately warranted [20]. Additionally, documentation of bone health, BMI, and quality of life will also be a contributing factor to the decision-making process regarding the need for GH treatment in young adulthood. For example, an increase in body fat and a decreased lean body mass 1 year after GH treatment interruption has been documented in a group of patients with partial GHD [43]. Thus, the clinical pathway for GHD patients involves numerous important health outcome variables.

The results of our analysis at the end of growth point to several critical questions pertaining to diagnosis in childhood, GH immunoassay sensitivity, and reassessment. In relation to diagnosis, there are a variety of tests used in childhood (i.e. ITT, ARG test, glucagon, etc.) as well as different assays. Indeed, the sensitivity of GH assays has improved over time and the GH assays that were used to diagnose many of the patients in the present study are not optimal. However, pediatric diagnosis is not solely based on test results but always corroborated with clinical and radiologic findings. Reassessment remains an important question. Secco et al. [28] identified predictors by correlating peak GH values at diagnosis (albeit using GH assays with suboptimal sensitivity) with outcomes in adulthood. They confirmed that the ITT is an accurate test in the reevaluation of GHD in children at the end of growth and that IGF-1 is a reliable marker for persistence of GHD. These data combined with the present study identify several predictors of persisting GHD in adulthood and underscore remaining questions. Importantly, these predictors should be confirmed by further studies with harmonized testing procedures and standardized cutoffs. Additionally, repeat testing during childhood may help improve the accuracy of diagnosis of GHD, and long-term follow-up is warranted to ensure that those cases of reversal remain normally functioning.

In conclusion, this retrospective study documents the natural history of GHD at the end of growth in a cohort of children with GHD excluding acquired forms. We identified several predictors of persisting GHD at final height: complete GHD at diagnosis, IGF-1 levels <-2 SDS following treatment cessation, pituitary malformation on MRI, and greater height gain during GH treatment. However, important questions remain regarding the continuation of GH treatment at the end of growth. These data underscore the paucity of data comparing dynamic testing regimens in this population that preclude the development of evidence-based guidelines. We propose using the ITT as the most extensively validated test in young adults during transition. Genetic findings on GHD may provide additional insights into the molecular basis for recovery of adolescents with GHD. Finally, long-term follow-up of these patients evaluating health-related outcomes may also contribute to the decision-making process for continuing GH treatment.


References


